Effects of sodium-glucose co-transporter 2 inhibitors on heart failure events in chronic kidney disease: a systematic review and meta-analysis
Pooled result · HF events in CKDResult — go to the resultHazard ratio 0.68 95% CI 0.63–0.73Authors' conclusion
Treatment with SGLT-2 inhibitors led to a significant reduction in HF events in patients with CKD.
Study context
- Population
- Patients with chronic kidney disease (CKD) at baseline or subgroups stratified by baseline estimated glomerular-filtration-rate (eGFR)
- Participants
- 89,191 patients12 studies
- Comparison
- SGLT2 inhibitors vs placebo
- Outcome
- Time to hospitalisation or urgent visit for worsening HF
Pooled result
HF events in CKD
Hazard ratio
0.68
95% CI 0.63–0.73
SGLT-2 inhibitorsvs Placebo
HR 0.68 (95% CI 0.63–0.73)
As reported in the abstract
Further pooled results
| Outcome | HR (95% CI) | |
|---|---|---|
| HF events by baseline eGFR (subgroup)SGLT-2 inhibitorsvs PlaceboeGFR <60 ml/min/1.73 m² | 0.68 (0.62–0.74) | |
| HF events by baseline eGFR (subgroup)SGLT-2 inhibitorsvs PlaceboeGFR ≥60 ml/min/1.73 m² | 0.76 (0.69–0.83) | |
| 0.512Hazard ratio (log scale) |
Heart failure (HF) events by type of SGLT-2 inhibitor (subgroup)
- Consistent treatment effect across all studied agents
- p-subgroup-analysis = 0.44
HF events, eGFR <60 ml/min/1.73 m², studies of diabetic patients only (sensitivity analysis)
- Even more pronounced effect in eGFR subgroup <60 ml/min/1.73 m²
- HR 0.62; 95% CI 0.54-0.70
- Sensitivity analysis
Original publication
Effects of sodium-glucose co-transporter 2 inhibitors on heart failure events in chronic kidney disease: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. Published 13 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →